Coronavirus: BioNTech chooses Singapore as its Asia Pacific vaccine hub – South China Morning Post

0 0
Read Time:23 Second

German drug maker BioNTech, whose coronavirus vaccine with Pfizer was the first to be approved in the United States and Europe for use last year, on Monday announced a new manufacturing facility in Singapore that would produce “several hundreds of millions” of mRNA-based vaccine doses a year.The move will boost BioNTech’s production capacities for vaccines and therapeutics for infectious diseases and cancer, and ensure it has rapid-response production capability for potential pandemic threats…Read More

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post COVID-19 Drives Uptake of Digital Payment Systems – The Diplomat
Next post Upgrading South Korean THAAD – The Diplomat

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published. Required fields are marked *